With an expected introductory price of ~$50,000 (assuming similar to PEG-IFN, when it was first introduced), we found that despite high efficacy of NAP treatment, its inclusion will have less impact in reducing the joint prevalence of two viruses than the existing best treatment option in Brazil (4-year TDF for mono-infections and 1-year Peg-IFN for co-infections) (Fig 4). The gene discussed is IFNA1; the disease is coinfection.